The Department of Veterans Affairs has decided to not include Biogen’s pricey new Alzheimer’s drug Aduhelm on its formulary, and its PBM even went so far as to recommend against offering it, noting “the lack of evidence of a robust and meaningful clinical benefit and the known safety signal.”
The decision, which is one of the first nationwide determinations on whether to cover the controversial new drug, also recommends that if Aduhelm is to be used by exception, then it should be used “only in highly selected patients by experts and centers that have the necessary diagnostic and management expertise — and only by those with the needed resources for close monitoring to assure safety,” Endpoints News has learned.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.